Tehran University of Medical Sciences

Science Communicator Platform

Share By
A99mtc-Tricine-Hynic-Labeled Peptide Targeting the Melanocortin-1 Receptor for Melanoma Imaging



Shamshirian D1 ; Erfani M2 ; Beiki D3 ; Hajiramazanali M1 ; Fallahi B3
Authors

Source: Iranian Journal of Pharmaceutical Research Published:2016

Abstract

Melanocortin-1 (MC1) receptor is an attractive melanoma-specific target for the development of α-MSH peptide based imaging and therapeutic agents. In this work a new lactam bridge α-MSH analogue was synthesized and radiolabeled with99mTc via HYNIC chelator and tricine as co-ligand. Also, stability in human serum, receptor bound internalization and tissue biodistribution in tumor bearing nude mice were thoroughly investigated. Radiolabeling with99mTc was performed at high specific activities (163MBq/nmol) with an acceptable labeling yield (>98%). The radioligand showed specific internalization into B16/F10 cells (13.35 ± 0.9% at 4 h). In biodistribution studies, a receptor-specific uptake was observed in MC1 receptor positive organ so that after 4 h the tumor uptake was 4.51 ± 0.11 % ID/g. Predominant renal excretion pathway with a highest accumulation of activity in tumor was observed for this radiopeptide. Obtained results show that the new designed labeled peptide conjugate can be a suitable candidate for diagnosis of metastatic melanomas. © 2016 by School of Pharmacy.
Related Docs
View other Related Docs
1. Development of a 99Mtc-Labeled Lactam Bridge-Cyclized Alpha-Msh Derivative Peptide As a Possible Single Photon Imaging Agent for Melanoma Tumors, Annals of Nuclear Medicine (2015)
2. Synthesis and Evaluation of a 99Mtc-Labeled Chemokine Receptor Antagonist Peptide for Imaging of Chemokine Receptor Expressing Tumors, Nuclear Medicine and Biology (2017)
3. Synthesis and Preliminary Evaluation of a New 99Mtc Labeled Substance P Analogue As a Potential Tumor Imaging Agent, Iranian Journal of Pharmaceutical Research (2015)
Experts (# of related papers)
View all Related Experts
Omid Sabzevari (7)
Davood Beiki (6)
Other Related Docs
4. Breast Tumor Targeting in Mice Bearing 4T1 Tumor With Labeled Cxcr4 Antagonist Analogue, International Journal of Peptide Research and Therapeutics (2021)
5. 177Lu-Labeled Cyclic Rgd Peptide As an Imaging and Targeted Radionuclide Therapeutic Agent in Non-Small Cell Lung Cancer: Biological Evaluation and Preclinical Study, Bioorganic Chemistry (2020)
6. 99Mtc Labeled Hynic-Edda/Tricine-Ge11 Peptide As a Successful Tumor Targeting Agent, Medicinal Chemistry Research (2018)
7. Development of a 99Mtc-Labeled Cxcr4 Antagonist Derivative As a New Tumor Radiotracer, Cancer Biotherapy and Radiopharmaceuticals (2018)
8. Design, Preparation and Biological Evaluation of a 177Lu-Labeled Somatostatin Receptor Antagonist for Targeted Therapy of Neuroendocrine Tumors, Bioorganic Chemistry (2020)
9. Design of a New 99M99mtc-Radiolabeled Cyclo-Peptide As Promising Molecular Imaging Agent of Cxcr4 Receptor: Molecular Docking, Synthesis, Radiolabeling, and Biological Evaluation, Current Radiopharmaceuticals (2024)
10. Radiosynthesis, Biological Evaluation, and Preclinical Study of a 68Ga-Labeled Cyclic Rgd Peptide As an Early Diagnostic Agent for Overexpressed Α V Β 3 Integrin Receptors in Non-Small-Cell Lung Cancer, Contrast Media and Molecular Imaging (2020)
11. Preparation and Preclinical Evaluation of a Gd(Ιιι)-Rgd Peptide for Mr Molecular Imaging in Non-Small Cell Lung Carcinoma (Nsclc), Iranian Journal of Nuclear Medicine (2023)
12. Synthesis and Radiolabeling of Glu-Urea-Lys With 99Mtc-Tricarbonyl-Imidazole-Bathophenanthroline Disulfonate Chelation System and Biological Evaluation As Prostate-Specific Membrane Antigen Inhibitor, Cancer Biotherapy and Radiopharmaceuticals (2023)